Drug Approval | February 21, 2025
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
The inspection was successfully completed
The inspection was successfully completed
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
Subscribe To Our Newsletter & Stay Updated
